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Summary
The use of microarray data has become quite commonplace in medical and scientific experiments. We
focus here on microarray data generated from cancer studies. It is potentially important for the discov-
ery of biomarkers to identify genes whose expression levels correlate with tumor progression. In this
article, we propose a simple procedure for the identification of such genes, which we term tumor
progression genes. The first stage involves estimation based on the proportional odds model. At the
second stage, we calculate two quantities: a q-value, and a shrinkage estimator of the test statistic is
constructed to adjust for the multiple testing problem. The relationship between the proposed method
with the false discovery rate is studied. The proposed methods are applied to data from a prostate
cancer microarray study.
Key words: Gene Expression; Metastasis; Mixture Models; Multiple Comparisons; Prostate
Cancer.
1 Introduction
The use of DNA microarray technology has allowed for new understanding of various cancers. The
hybridization of cDNA to arrays containing thousands of genes and ESTs permits a global genome-
wide evaluation of tumor samples. This technology has has led to development of statistical methodol-
ogy in various areas of microarray data analysis, such as methods for differential expression (Efron
et al., 2001; Dudoit et al., 2002b), clustering (Eisen et al., 1998) and classification (Hastie et al., 2000;
Dudoit et al., 2002a).
The motivating example is from a microarray experiment in prostate cancer (Dhanasekaran et al.,
2001). We have profiled tissue samples from various stages of prostate cancer (e.g., normal adjacent
prostate, benign prostatic hyperplasia, localized prostate cancer, advanced metastatic prostate cancer).
The samples are linked to a patient clinical database that has other parameters, such as Gleason score,
survival time and status, and time to PSA recurrence. One of the main hypotheses of interest to
scientists is that there exist distinct sets of genes and proteins dictate progression from precursor
lesion, to localized disease, and finally to metastatic disease. This hypothesis is biological in nature
and is focused upon learning about which genes are involved in cancer pathways. We will refer to
genes satisfying this hypothesis as tumor progressor genes.
The ideal design for studying development of gene expression profiles in tumors would be a lon-
gitudinal experiment. The tumor is commonly thought to originate as a progenitor cell and goes
through several stages of progression (e.g., benign hyperplasia, in situ). Such a model for tumor pro-
gression has been postulated by Fearon and Vogelstein (1990). If it were possible to sample the same
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tumor in these various stages of development and to generate gene expression profiles for each of the
time points, then this would provide the optimal setting for studying the effect of gene expression pro-
files on tumor progression. While this is possible for studying tumor volume progression in mouse mod-
els (Ferrante et al., 2000), this is not feasible for humans as tumor tissue is completely resected from the
patient. The data typically available are the gene expression profiles for the tumor sampled at one point
of time in the tumor progression for a given patient. One could perform such an experiment using tumor
cell lines, but then there is the question of whether these results would generalized to human tissue.
One can view the gene expression profile as a high-dimensional biological property of the tumor.
There has been a rich literature existing on statistical models for tumor progression in which the
property considered was size of the tumor (Kimmel and Flehinger, 1991; Xu and Prorok, 1997). How-
ever, no such development has occurred for gene expression profile and its effects on tumor progres-
sion. By incorporating clinical information on stage of the tumor (e.g., precursor lesion, localized
prostate cancer and metastatic lesion), one can utilize microarray data potentially in a more efficient
fashion. However, an important feature that must be considered is that many of the genes are nonin-
formative about tumor progression. In this article, we seek to develop statistical methods for character-
izing the relationship of gene expression profile on tumor progression. The gene expression profile is
treated as the feature of the tumor that we wish to associate with clinical progression. While there
have many proposals for assessing differential expressioneteps in the setting of two or more groups,
there has been relatively little literature on assessing association in the situation where the phenotype
is an ordinal response with more than two levels.
We develop and describe two simple methods to address this goal. The procedure involves gene-by-
gene estimation using the proportional odds model (Agresti, 2002) at the first stage. At the second
stage, one of two approaches are used. One is to calculate q-values (Storey, 2002; Storey and Tibshi-
rani, 2003) based on the univariate p-values. The second is to calculate shrinkage estimators of the
test statistics are constructed in order to adjust for the multiple testing problem. This is done using
James-Stein type estimators; a novel consideration is that shrinkage must be done towards two targets
in the current setting. The shrinkage estimators are meant to provide complementary information to
the q-values; we discuss this in the context of the prostate cancer example. The eteps structure of this
paper is as follows. In Section 2, we describe the data structures and the statistical procedures for
analyzing the effects of gene expression on tumor stage. The methods are applied to the previously
mentioned prostate cancer data in Section 3. We conclude with some discussion in Section 4.
2 Systems and Methods
2.1. Notations and preliminaries
Let D denote the stage of disease; we assume that it takes values ð1; . . . ; dÞ, where increasing num-
bers corresponding to progressively advanced stages of disease. Thus, D will be treated as an ordinal
variable here and in the sequel. We will assume that d > 2. Let X denote the G-dimensional gene
expression profile. We observe the data ðDi;XiÞ, i ¼ 1; . . . ; n, iid observations from the joint distribu-
tion of ðD;XÞ. In most situations we consider, G is typically much larger than n. We will assume
throughout the paper that the gene expression data X1; . . . ;Xn have been suitably preprocessed and
normalized both within and across slides.
2.2. Proportional odds model
Define Pr ðAÞ to be the probability of the event A. One simple model for associating gene expression
with stage of disease is the proportional odds model (Agresti, 2002, § 7.2.2): for r ¼ 1; . . . ; d,
log
Pr ðDi  rÞ
Pr ðDi > rÞ
 
¼ arg þ bgXig; ð1Þ
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where ða0g; . . . ;adgÞ are gene-specific cutpoints, bg is a gene-specific regression coefficient, and Xig is
the g-th component of Xi ði ¼ 1; . . . ; n; g ¼ 1; . . . ;GÞ. Note that arg is increasing in r since
Pr ðDi  r jXigÞ is increasing in r. Positive values of bg indicate that higher values of gene expression
are associated with increased odds that stage D is an early stage, while negative values of bg demon-
strate the converse.
An alternative motivation of model (1) is to use a latent underlying random variable Zig, where
Zig þ bgXig has a standard logistic distribution, i.e. Pr ðZig  bgXig  uÞ ¼ exp ðuÞ=f1þ exp ðuÞg.
Then the event fDi ¼ dg corresponds to the event ad1 < Zig  ad. This implies that
Pr ðDi  dÞ ¼ Pr ðZi  adÞ
¼ Pr ðZi þ bgXig  ad þ bgXigÞ
¼
exp ðad þ bgXigÞ
1þ exp ðad þ bgXigÞ
:
The proportional odds model can be fit using many standard software packages, such as SAS or S-Plus.
Here and in the sequel, we will derive procedures for making inferences using Tg ¼ jb̂gj=cSEðb̂gÞ
ðg ¼ 1; . . . ;GÞ, the usual Wald statistic based on b̂g.
2.3. Multiple testing adjustment and false discovery rates
In most microarray studies, G is much larger than n. The model in (1) is univariate and does not
incorporate information across genes. One method of doing this is to incorporate a second stage in
which T1; . . . ; TG is a random sample from a mixture distribution:
Tg
iid
p0FU þ ð1 p0ÞFV : ð2Þ
In model (2), p0 represents the proportion of genes that are noninformative about tumor progression,
while the remaining percentage, 1 p0 are indicators of gene progression. FU and FV are the distribu-
tion functions for the noninformative and informative tumor progressor genes, respectively. We will
take FU to be a standard normal distribution, here and in the sequel.
It turns out that the model (1)–(2) has a connection with multiple testing procedures based on the
false discovery rate (Benjamini and Hochberg, 1995; Storey, 2002). We consider the G univariate null
hypotheses H0g: bg ¼ 0, g ¼ 1; . . . ;G. Mimicking the arguments of Theorem 1 in Storey (2002), we
have that based on the two-stage model (1)–(2), the gene-specific false-discovery rate is given by
FDRg ¼ PrðH0 j Tg 2 RÞ, where R is the rejection region for the gth test statistic Tg, g ¼ 1; . . . ;G.
One could then use the following algorithm for the estimation of gene-specific false-discovery rates,
following Storey (2002):
Algorithm 1:
1. Fit (1) for each gene g using maximum likelihood for g ¼ 1; . . . ;G.
2. Calculate a p-value using Tg  jb̂gj=cSEðb̂gÞ, g ¼ 1; . . . ;G.
3. Let p1; . . . ; pG denote the G p-values. Estimate p0, the proportion of nondifferentially expressed









where RðgÞ ¼ #fpi  gg.
70 D. Ghosh and A. M. Chinnaiyan: Associating Gene Expression with Ordinal Data
# 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biometrical-journal.com
4. For any rejection region of interest ½0; g, estimate the FDR as
dFDRðgÞ ¼ p̂0 g
F̂PðgÞ
 f1 ð1 gÞGg:
In this algorithm, l takes values between 0 and 1 and plays the role of a smoothing parameter. The
smaller the value of l, the fewer the p-values that are included in the calculation of RðgÞ. This leads
to decreased bias but increased variability.
There are two issues in this algorithm that need to be resolved. The first is method of calculating
the p-value in step 2 of the algorithm. We use permutation methods where the sample labels
D1; . . . ;Dn are permuted. Note the validity of the method depends on the assumption that under the
global null hypothesis of no difference in progression groups for any of the genes, the data are ex-
changeable. The second issue is the choice of l. Observe that there is a bias-variance tradeoff in the
choice of l. It turns out that the bias of p0 is minimized when l ¼ 1. This leads to the following
algorithm to determine p0, described by Storey and Tibshirani (2003):
Algorithm 2:
1. Order the G p-values as pð1Þ  pð2Þ      pðGÞ.





l ¼ 1; . . . ; L.
3. Fit a cubic smoothing spline to the values fll; p̂0ðllÞg, l ¼ 1; . . . ; L.
4. Estimate p0 by the interpolated value at l ¼ 1.
Given this algorithm, one can then estimate gene-specific q-values (Tusher et al., 2001; Storey and
Tibshirani, 2003) for the individual genes. The q-value is defined to be the smallest FDR at which a






and for i ¼ G 1, G 2; . . . ; 1, qðpðiÞÞ ¼ min ðp̂0GpðiÞ=i; p̂ðiþ1ÞÞ. This guarantees that the q-values
will be monotonically increasing as a function of p-values.
2.4. Decision-theoretic estimation procedures
An alternative interpretation of the mixture distribution (2) is that it provides two targets for estima-
tion: the target under the null hypothesis and that under the alternative hypothesis. Thus, an alternative
to the q-value method of Storey (2002) is to develop shrinkage estimators for the mixture model. One
can then view the shrinkage estimators as adjusted estimates of bg on a standardized scale, accounting
for the multiple comparisons issue.
Following the arguments of George (1986), a James-Stein approach involves constructing shrinkage
estimators for PðH ¼ 0jTiÞ. We calculate for i ¼ 1; . . . ;G,
TJSi ¼ p0ðTiÞTJS0i þ f1 p0ðTiÞgTJS1i ; ð3Þ
where
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TJS1i ¼ Ti  1 ^
ðG 1Þs2VPn
i¼1 ðTi  m1Þ
2
" #
ðTi  mVÞ; ð4Þ
p0ðzÞ ¼
p0FUðzÞ




where mV and s
2
V are the mean and variance corresponding to FV , and FZ is the population cumulative
distribution function for T. These adjusted statistics are shrunken statistics that account for the multi-
ple testing problem.
In fact, there are many choices for the definition of (5). We have defined it in terms of the cumula-
tive distribution functions for the two components of the mixture model. Suppose we consider an
alternative definition for (5):
~p0ðpÞ ¼
p0fUðpÞ
p0fUðpÞ þ ð1 p0ÞfVðpÞ
; ð6Þ
where fU and fV are the density functions for U and V . Then (6) is precisely the local false discovery
rate (Efron et al., 2001) based on p. We prefer the use of (5) to (6) because of variance issues. In
particular (6) will have greater variance than (5) because density estimates tend to be much more
variable than those based on the cumulative distribution function.
The proposed methodology adjusts the univariate Wald statistics for the multiple testing problem by
shrinkage in which the shrinkage weights (5) or (6) are data-adaptive. Here and in the sequel, we
consider (5). Suppose that a large fraction of null hypotheses are true, i.e. p0 	 1. Then based on (5)
and (3), the statistics will be shrunk towards 0. By contrast, if a majority of the null hypotheses are
false, then the adjusted statistics will be closer to the mean of the distribution of the Wald statistics
under the alternative hypothesis. This shows that the methodology is data-adaptive. In addition, one
can view the estimated quantities as Empirical Bayes estimators of the estimation targets in (2), simi-
lar to what has been done with the location parameter in normal probability models (Berger, 1985,
Section 4.5).
Another interpretation of (3) is as a doubly-shrunken test statistic, shrunk towards each component
of the mixture. This idea was originally proposed by George (1986) in the context of a normal prob-
ability model. There are several differences between his work and ours. First, we are considering a
mixture model for the test statistics, which is fundamentally different from the normal model consid-
ered by George (1986). In addition, note that there are unknown population quantities in (4) and (5)
that need to be estimated. George (1986) provides no estimation procedure from observed data.
Observe that (2) implies the following result for the cumulative distribution:
FZðtÞ ¼ p0FUðtÞ þ ð1 p0ÞFVðtÞ: ð7Þ





We can estimate FZ in (8) using the empirical distribution function of the observed statistics. Provided
we have an estimator of p0, we can then estimate FV and subsequently the mean and variance in (4).
Thus, the outstanding issue becomes one of estimating p0. We use the estimator described in Algo-
rithm 2.
3 Prostate Cancer Data
The dataset we will be using to illustrate the ideas in the paper is from a molecular profiling study in
prostate cancer (Dhanasekaran et al., 2001). The benign and malignant prostate tissues were analyzed
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using a 9984 element (10 K) human cDNA microarray. A two-channel (Cy5/Cy3) scheme was uti-
lized. While there are 9984 genes on the original array and 101 samples from d ¼ 3 tumor classes:
benign precursor, localized prostate cancer and metastatic prostate cancer. We did some preprocessing
to reduce the number of genes considered; namely, we filtered out genes that are reported as missing
in more than 10% of the samples. This left a total of G ¼ 7910 genes for analysis. We first performed
the analysis based on fitting the proportional odds model. A spreadsheet containing gene names, esti-
mated regression coefficients and associated Wald statistics can be downloaded as the file from the
following website:
http:==www:sph:umich:edu=ghoshd=COMPBIO=TPROG=pgenes1:csv:
In addition, a histogram of the t-statistics is given in Figure 1.
Based on permutation methods, we calculated p-values and then applied the false discovery rate
estimation procedure of Storey and Tibshirani (2003). The results are summarized in Figure 2. Based
on the graphs, 1582 genes have q-values less than 0.001, 753 have those less than 0.0001, and 313
less than 0.00001. One point of note is that the proportion of nondifferentially expressed genes is only
0.3. This is relatively low but is consistent with estimates we have found on other cancer datasets, in
our experience. The main reason we think that the estimate is so low is because of confounding of the
disease comparison with other factors.
In studies such as these, investigators are typically interested in developing a gene list of candidate
biomarkers that they would be interested in performing further validation analyses, such as immuno-
histochemistry or quantitative RT-PCR. We focus on two results from such an analysis. The first is the
identification of homologs of mammalian transcription factors. Among the top 100 genes are a homo-
log of a yeast transcription factor (Sec23 – Hs. 753381), a homolog of the FAT tumor suppressor in
Drosophila (Hs. 591266), a homolog of a transcription factor in Xenopus laevis (Hs. 760299), and
another Drosophila transcription factor homolog, frizzled, (Hs. 298122). Given the recent discovery





















Figure 1 Histogram of Wald statistics for prostate cancer gene ex-
pression data.
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(Varambally et al., 2002) of a prostate cancer biomarker that is a homolog of a Drosophila transcrip-
tion factor, EZH2, these genes are of interest to the investigator to identify other homologs of mam-
malian transcription factors that might be involved in cancer dysregulation.
Another finding is the decreased expression of cell surface and cell adhesion genes and products in
the top 200 list. This includes genes such as catenin (Hs. 364921), moesin (Hs. 131362), integrin (Hs.
502527), and integrin, beta 1 (Hs. 343072). The transformation of a cancer from nonmetastatic to
metastatic involves the development of a motile phenotype that allows the cancer cells to migrate
from the site of origin to other sites. This involves step such as the epithelial-mesenchymal transition,
cellular transformation and loss of cell adhesion to epithelial cells. The results of the analysis here are
consistent with such a conceptual model for tumorigenesis. A caveat of these results is that they are
not confirmatory but rather hypothesis-generating. Further computational and/or biological experi-
ments would be needed to validate these findings.
Next, we applied the proposed Empirical Bayes method for calculating doubly shrunken Wald sta-
tistics in the analysis of the microarray data. A plot comparing their values to those of the original
statistics is given in Figure 3. We find several interesting results. First, the scale of significance is
drastically shrunk using the adjusted scale (vertical axis) versus the original scale (horizontal axis).
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Figure 2 Output of proportional odds method combined with false discov-
ery rate estimation procedures. The plot in the upper left-hand corner shows
the estimated false discovery rate using the method of Storey and Tibshirani
(2003). The upper right-hand plot shows the conversion of p-values to q-
values as discussed in the Proposed Methods and Results section. The
graph on the lower left-hand side shows the number of significant tests as a
function of q-value cut-off. The lower right-hand graph displays the ex-
pected false positives as a function of number of significant tests; the esti-
mated false discovery rate is the ratio of these quantities.
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This serves to illustrate the fact that shrinkage leads to significant downweighting of the strength of
evidence in the multiple testing situation. One can imagine combining the q-value procedure with the
double shrinkage estimators proposed here in the following procedure:
1. Select all genes that have a q-value less than some cut-off;
2. Report the double shrunken estimators as estimates of the standardized effect size for those
genes selected in 1.
Because the q-values have an Empirical Bayes interpretation, as do the double shrinkage estimators,
one can view this as an approximate Bayesian testing procedure. The sampling distribution of the test
statistics does not depend on the stopping rule specified in 1.
Finally, some mention of costs is warranted. The use of FDR is appropriate if the cost of a false
discovery is proportional to the proportion of false discoveries. However, if the cost of false discov-
eries is proportional to the total number of false discoveries, then one should seek to have control of
the generalized familywise error rate (Hommel and Hoffman, 1988; Lehmann and Romano, 2005).
4 Discussion
In this article, we have described a simple approach using Empirical Bayes methods for identifying
genes that associate with tumor progression in cancer studies using microarray data. These techniques
complement the multiple testing methods currently available for microarray data (Efron et al., 2001;
Dudoit et al., 2002b).
The estimation procedure at the first step involves use of a proportional odds model. However, any
other model for ordinal categorical data (Agresti, 2002) could also be used there. For the estimation
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Figure 3 Plot of shrunken Wald statistics (y-axis) against absolute value
of Wald statistics (x-axis) for prostate cancer gene expression data.
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of the doubly shrunk Wald statistics, we used the estimator of p0 from the algorithm of Storey and
Tibshirani (2003). However, there are several other potential estimators of the proportion of null
hypotheses that could be used as well (Pounds and Cheng, 2004; Dalmasso et al., 2005).
There are two crucial assumptions embodied in the mixture model posited for the test statistics in
(2). The first assumption in the methods developed so far is that there is no confounding of gene
expression by other clinical factors. One could imagine that sample characteristics, such as age of the
patient or tissue heterogeneity, could confound the association between gene expression and tumor
progression. If these characteristics have been measured, then we would extend the proportional odds
model approach by including them as covariates. As discussed in Ghosh and Chinnaiyan (2005), the
validity of p-values derived from permutation testing in this setting would be questionable. Another
reason that the p-values might not be quite correct is that the permutation assumes all genes have no
differential expression, while in actuality, the model (2) assumes that some fraction of hypotheses
testing are in actuality not true. Thus, the permutation procedure would work better if we were to
screen out differentially expressed genes. This idea has been suggestetepsed by several authors, among
them Xie et al. (2005) and Scheid and Spang (2006).
The second assumption deals with the choice of the null distribution. We assume that the compo-
nent corresponding to the null hypotheses is a normal distribution with mean zero and variance one.
This might not be the right null to use (Efron, 2004). We are currently researching the use of alterna-
tive distributions for the null hypothesis.
We have attempted to treat gene expression as a biological property of the tumor sample and corre-
late it with tumor progression. An alternative approach, not considered in this paper, would be to
formulate a stochastic modelling approach in which a mechanistic model for gene expression develop-
ment is postulated. This has precedents in the mathematical modelling literature (Yakovlev and Tsodi-
kov, 1996).
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